A phase II trial of peplomycin in squamous cell carcinoma of the lung.

Abstract

A phase II trial has been performed in squamous cell carcinoma of the lung using peplomycin. This compound is a bleomycin analogue with less pulmonary toxicity and a broader antitumor effect than bleomycin in experimental animal systems. Twenty-one evaluable patients were treated using a dose schedule of 5 mg/m2 twice weekly intravenously. None of the patients had previously received radiation or chemotherapy. The median dose of peplomycin received was 160 mg (range 45-254). One patient obtained a partial remission lasting 3 months. One out of 21 patients developed clinical symptoms and a decrease in the lung function test performed during treatment indicative of toxicity. Other manifestations of toxicity are comparable to those of bleomycin.

• Authors: P G Sørensen, M Rørth, H H Hansen, P Dombernowsky, H Høst
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 19 Issue 1 Pg. 25-7 (Jan 1983) ISSN: 0277-5379 [Print] England
• PMID: 6189718 (Publication Type: Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Bleomycin
• Peplomycin

Topics

• Aged
• Antibiotics, Antineoplastic (adverse effects, therapeutic use)
• Bleomycin (adverse effects, therapeutic use)
• Carcinoma, Squamous Cell (drug therapy)
• Drug Evaluation
• Humans
• Lung Neoplasms (drug therapy)
• Middle Aged
• Peplomycin